Paul Hastings LLP advised Orchestra BioMed on the deal. Orchestra BioMed, a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced the closing of a $110...
Orchestra BioMed’s $110 Million Series D Financing
RIV Capital’s Acquisition of Etain Companies
Paul Hastings LLP represented RIV Capital on the deal. RIV Capital announced its definitive agreement to acquire ownership and control of Etain LLC and Etain IP LLC,...